Brokerages Expect Sangamo Therapeutics, Inc. (SGMO) Will Announce Quarterly Sales of $11.28 Million

Wall Street analysts expect Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to post sales of $11.28 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Sangamo Therapeutics’ earnings, with estimates ranging from $5.85 million to $14.70 million. Sangamo Therapeutics reported sales of $8.92 million in the same quarter last year, which would suggest a positive year over year growth rate of 26.5%. The business is scheduled to issue its next earnings results on Tuesday, February 27th.

According to Zacks, analysts expect that Sangamo Therapeutics will report full year sales of $11.28 million for the current financial year, with estimates ranging from $34.00 million to $38.20 million. For the next fiscal year, analysts expect that the business will post sales of $56.63 million per share, with estimates ranging from $28.70 million to $121.30 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Sangamo Therapeutics.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. The company had revenue of $11.81 million during the quarter, compared to analysts’ expectations of $10.37 million. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The firm’s quarterly revenue was up 333.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.27) EPS.

SGMO has been the subject of a number of research analyst reports. Barclays PLC assumed coverage on Sangamo Therapeutics in a report on Wednesday. They set an “overweight” rating for the company. Wedbush reaffirmed a “hold” rating and issued a $6.00 price target on shares of Sangamo Therapeutics in a research report on Wednesday, November 15th. Zacks Investment Research raised Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Wednesday, November 15th. Piper Jaffray Companies raised Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 price target on the stock in a research report on Wednesday, November 15th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $18.00 target price on shares of Sangamo Therapeutics in a research report on Friday, October 13th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $17.40.

In related news, Director Saira Ramasastry sold 5,000 shares of Sangamo Therapeutics stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $14.67, for a total value of $73,350.00. Following the sale, the director now directly owns 5,000 shares in the company, valued at $73,350. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director William R. Ringo sold 31,000 shares of Sangamo Therapeutics stock in a transaction that occurred on Wednesday, September 20th. The shares were sold at an average price of $14.37, for a total value of $445,470.00. Following the completion of the sale, the director now owns 31,800 shares in the company, valued at $456,966. The disclosure for this sale can be found here. Insiders sold a total of 66,000 shares of company stock worth $972,570 over the last quarter. Company insiders own 5.50% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Quantbot Technologies LP purchased a new stake in shares of Sangamo Therapeutics in the third quarter valued at approximately $118,000. Amalgamated Bank purchased a new stake in shares of Sangamo Therapeutics in the third quarter valued at approximately $158,000. Blair William & Co. IL boosted its stake in shares of Sangamo Therapeutics by 4.3% in the second quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 500 shares in the last quarter. Aperio Group LLC purchased a new stake in shares of Sangamo Therapeutics in the second quarter valued at approximately $108,000. Finally, Great West Life Assurance Co. Can boosted its stake in shares of Sangamo Therapeutics by 150.3% in the third quarter. Great West Life Assurance Co. Can now owns 12,767 shares of the biopharmaceutical company’s stock valued at $182,000 after buying an additional 7,667 shares in the last quarter. Hedge funds and other institutional investors own 63.29% of the company’s stock.

Shares of Sangamo Therapeutics (SGMO) opened at $15.10 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.64 and a quick ratio of 5.64. Sangamo Therapeutics has a twelve month low of $2.65 and a twelve month high of $17.06.

ILLEGAL ACTIVITY NOTICE: “Brokerages Expect Sangamo Therapeutics, Inc. (SGMO) Will Announce Quarterly Sales of $11.28 Million” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/07/brokerages-expect-sangamo-therapeutics-inc-sgmo-will-announce-quarterly-sales-of-11-28-million.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply